Clinical trial NCT03862040: Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
Official title: An Open-label, Multicenter, Single-arm, Phase 1 Study to Assess the Intrapulmonary Concentrations of Cefiderocol at Steady State in Hospitalized Subjects With Known or Suspected Bacterial Pneumonia on Treatment With Standard of Care Antibiotics and Requiring Mechanical Ventilation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Bacterial Pneumonia
Lead sponsor: Shionogi Inc.
Sponsor class: INDUSTRY
First posted: 2019-03-05
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary purpose of the study is to determine the degree of penetration of cefiderocol into infected lung tissue in hospitalized adults with bacterial pneumonia who are being mechanically ventilated.


Eligibility criteria: Inclusion Criteria:

1. Subject is 18 years or older at the time written informed consent is obtained
2. Subject has provided written informed consent or informed consent has been provided by subject's legally authorized representative
3. Subject has a diagnosis or suspicion of bacterial pneumonia (even if later known that the subject does not have bacterial pneumonia, discontinuation of the study is not necessary)
4. Subject is hospitalized and receiving standard of care antibiotic treatment for pneumonia
5. Subject is mechanically ventilated or expected to be mechanically ventilated at least 48 hours (or 72 hours for subjects with severe renal impairment) after the first dose of cefiderocol
6. Subject has a life expectancy of at least 3 weeks from the Screening visit
7. Subject is male (no contraception required) or female and meets 1 of the following criteria:

   1. Surgically sterile (has had a hysterectomy and/or bilateral oophorectomy, or a bilateral salpingectomy or tubal ligation for the purpose of contraception for at least 6 weeks with appropriate documentation of such surgery)
   2. Postmenopausal (defined as older than 45 years of age with cessation of regular menstrual periods for at least 6 months and a follicle-stimulating hormone level of \> 40 mIU/mL, or amenorrhea for at least 12 months)
   3. Of childbearing potential and using combined (estrogen and progestogen) or progestogen-only hormonal contraception associated with inhibition of ovulation (including oral, intravaginal, injectable, implantable, and transdermal contraceptives), or an intrauterine device (IUD), or intrauterine hormone-releasing system for the entire duration of the study
   4. Of childbearing potential and practicing abstinence as a preferred and usual life style and/or agrees to continue practicing abstinence from Screening for the entire duration of the study
   5. Of childbearing potential and whose sole heterosexual partner has been successfully vasectomized and agrees to not have other heterosexual partners for the entire duration of the study

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

1. Subject has a chemical pneumonia that does not require antibiotic treatment (including aspiration of gastric acid, inhalation injury). The term chemical pneumonia refers to the aspiration of substances that are toxic to the lower airways causing chemical burn and injuries in the airway.
2. Subject has a history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment)
3. Subject has extensive cystic lesion(s) or severe structural abnormality (eg, cystic fibrosis, emphysema, cystic lesions of sarcoidosis or tuberculosis, postobstructive pneumonia due to lung cancer, etc) of the lung that hinders recovery of bronchoalveolar lavage fluid (BALF)
4. Subject is receiving peritoneal dialysis
5. Subject has severe renal impairment requiring hemodialysis (HD) or end-stage renal disease requiring HD
6. Subject is in refractory septic shock defined as persistent hypotension despite adequate fluid resuscitation or despite vasopressive therapy at Screening
7. Subject is a female who has a positive pregnancy test at Screening or who is lactating
8. Subject has received another investigational drug within 30 days prior to Screening
9. Subject has previously participated in this clinical study and has received at least 1 dose of cefiderocol within 7 days
10. Subject has any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data

Primary outcomes:
measure: Concentration of Cefiderocol in Epithelial Lining Fluid
timeFrame: At the third dosing (or sixth dosing for participants with severe renal impairment; 16 or 40 hours after first dose, respectively), at 3 hours after the start of the infusion or 2 hours after the end of infusion.
measure: Ratio of the Concentration of Cefiderocol in Epithelial Lining Fluid Relative to Plasma
timeFrame: At the third dosing (or sixth dosing for participants with severe renal impairment; 16 or 40 hours after start of the first dose, respectively), at 3 hours after the start of the infusion or 2 hours after the end of infusion.
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Anschutz Medical Campus
state: Colorado
city: Hartford
country: United States
facility: Hartford Hospital
state: Connecticut
city: Jacksonville
country: United States
facility: University of Florida
state: Florida
city: Miami
country: United States
facility: U Miami Health Tower
state: Florida
city: Chicago
country: United States
facility: North Western University
state: Illinois
city: Omaha
country: United States
facility: Creighton University
state: Nebraska
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
Study officials:
affiliation: Shionogi
name: Shionogi Clinical Trials Administrator Clinical Support Help Line
role: STUDY_DIRECTOR
References: